ThinkstockBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep Vein Thrombosis and Pulmonary Embolisms. Each year an…
ThinkstockWith the biotech space having its usual volatile ups and downs this year, the analysts at Stifel have stepped back into the coverage world and have reinitiated research analysis on some of the top…
MannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week’s news that Sanofi (NYSE: SNY) will become its global partner for its inhalable insulin Afrezza. There has been just one small, or…
ThinkstockDendreon Corp. (NASDAQ: DNDN) has turned into one of those unsettling biotech stories: It went from great promise, to high hopes, to a reality check, and now to an incredibly uncertain future. Dendreon hit…
ThinkstockThe short interest report is out for the July 31 settlement date and 247 Wall St. is focusing on the active short selling in the biotech sector. Short sellers are often active in biotech…
ThinkstockTekmira Pharmaceuticals Corp. (NASDAQ: TKMR) has made a name for itself pioneering new experimental treatments in the wake of the most recent Ebola scare. Ebola is considered one of the deadliest viruses on the planet…
ThinkstockAfter being absolutely rocked back in the spring, the biotech sector has bounced back smartly. Even a bubble comment from the head of the Federal Reserve Janet Yellen didn’t stop the return of the biotechnology…
ThinkstockMannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of its strategy on how to get its Afrezza inhalable insulin to the market. The…
Thoratec was the king of the stock drops in Wednesday's after-hours trading session. We have seen multiple analyst downgrades as well.
We have seen four biotech research reports in which the analysts covering these stocks are now calling for upside of 100% -- or even higher!
A new research report from the analysts at Stifel notes that the managed care organizations (MCOs) have posted solid results and raised earnings estimates, and they have been sold off.
ThinkstockThe world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to whether two Americans who contracted Ebola in Africa should have been brought back for treatment.…
This week's layoff announcement by Amgen may have investors and the public starting to rethink what "being a biotech company" really means.
Drug giants Merck and Pfizer reported better-than-expected second-quarter 2014 results before markets opened Tuesday morning.
AbbVie reported better-than-expected second-quarter 2014 results before markets opened Friday morning, due in part to strong sales of its Humira anti-inflammatory drug.